Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.28 USD | +1.08% | -3.11% | -27.55% |
Sales 2024 * | 529M 42.35B | Sales 2025 * | 681M 54.5B | Capitalization | 3.04B 244B |
---|---|---|---|---|---|
Net income 2024 * | -1M -80.05M | Net income 2025 * | 120M 9.61B | EV / Sales 2024 * | 6.02 x |
Net Debt 2024 * | 139M 11.13B | Net Debt 2025 * | 24.31M 1.95B | EV / Sales 2025 * | 4.51 x |
P/E ratio 2024 * |
-1,694
x | P/E ratio 2025 * |
26.5
x | Employees | 517 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.81% |
Latest transcript on Amicus Therapeutics, Inc.
1 day | +1.08% | ||
1 week | -3.11% | ||
Current month | -12.73% | ||
1 month | -13.32% | ||
3 months | -16.69% | ||
6 months | -4.01% | ||
Current year | -27.55% |
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 31/03/06 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 20/08/23 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 30/06/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 31/03/06 |
Lynn Bleil
BRD | Director/Board Member | 60 | 10/09/18 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 26/06/19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.91% | 16 M€ | -8.49% | ||
0.32% | 0 M€ | 0.00% | - | |
0.29% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 10.28 | +1.08% | 1,714,709 |
25/04/24 | 10.17 | -3.51% | 4,002,520 |
24/04/24 | 10.54 | -1.59% | 1,821,018 |
23/04/24 | 10.71 | -1.02% | 5,091,023 |
22/04/24 | 10.82 | +1.98% | 4,620,529 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.55% | 3.04B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FOLD Stock